Literature DB >> 25766658

Nuclear factor of activated T cells in cancer development and treatment.

Jiawei Shou1, Jing Jing2, Jiansheng Xie3, Liangkun You1, Zhao Jing1, Junlin Yao1, Weidong Han4, Hongming Pan5.   

Abstract

Since nuclear factor of activated T cells (NFAT) was first identified as a transcription factor in T cells, various NFAT isoforms have been discovered and investigated. Accumulating studies have suggested that NFATs are involved in many aspects of cancer, including carcinogenesis, cancer cell proliferation, metastasis, drug resistance and tumor microenvironment. Different NFAT isoforms have distinct functions in different cancers. The exact function of NFAT in cancer or the tumor microenvironment is context dependent. In this review, we summarize our current knowledge of NFAT regulation and function in cancer development and treatment. NFATs have emerged as a potential target for cancer prevention and therapy.
Copyright © 2015 The Authors. Published by Elsevier Ireland Ltd.. All rights reserved.

Entities:  

Keywords:  Calcineurin; Drug resistance; Metastasis; NFAT; Tumor microenvironment

Mesh:

Substances:

Year:  2015        PMID: 25766658     DOI: 10.1016/j.canlet.2015.03.005

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  40 in total

Review 1.  Ca2+ as a therapeutic target in cancer.

Authors:  Scott Gross; Pranava Mallu; Hinal Joshi; Bryant Schultz; Christina Go; Jonathan Soboloff
Journal:  Adv Cancer Res       Date:  2020-07-09       Impact factor: 6.242

Review 2.  The role of nuclear factor of activated T cells in pulmonary arterial hypertension.

Authors:  Rui Chen; Jinchuan Yan; Peijing Liu; Zhongqun Wang; Cuiping Wang; Wei Zhong; Liangjie Xu
Journal:  Cell Cycle       Date:  2017-01-19       Impact factor: 4.534

Review 3.  Autotaxin, a lysophospholipase D with pleomorphic effects in oncogenesis and cancer progression.

Authors:  Lorenzo Federico; Kang Jin Jeong; Christopher P Vellano; Gordon B Mills
Journal:  J Lipid Res       Date:  2015-05-14       Impact factor: 5.922

4.  Identification of Novel Nuclear Factor of Activated T Cell (NFAT)-associated Proteins in T Cells.

Authors:  Christian H Gabriel; Fridolin Gross; Martin Karl; Heike Stephanowitz; Anna Floriane Hennig; Melanie Weber; Stefanie Gryzik; Ivo Bachmann; Katharina Hecklau; Jürgen Wienands; Johannes Schuchhardt; Hanspeter Herzel; Andreas Radbruch; Eberhard Krause; Ria Baumgrass
Journal:  J Biol Chem       Date:  2016-09-16       Impact factor: 5.157

5.  Gene expression in regenerating and scarring tails of lizard evidences three main key genes (wnt2b, egfl6, and arhgap28) activated during the regulated process of tail regeneration.

Authors:  Massimo Degan; Luisa Dalla Valle; Lorenzo Alibardi
Journal:  Protoplasma       Date:  2020-08-27       Impact factor: 3.356

6.  Driving mesenchymal transition in glioblastoma.

Authors:  Michael Platten
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

7.  NFAT restricts osteochondroma formation from entheseal progenitors.

Authors:  Xianpeng Ge; Kelly Tsang; Lizhi He; Roberto A Garcia; Joerg Ermann; Fumitaka Mizoguchi; Minjie Zhang; Bin Zhou; Bin Zhou; Antonios O Aliprantis
Journal:  JCI Insight       Date:  2016-04

8.  NFAT2-HDAC1 signaling contributes to the malignant phenotype of glioblastoma.

Authors:  Yifu Song; Yang Jiang; Dongxia Tao; Zixun Wang; Run Wang; Minghao Wang; Sheng Han
Journal:  Neuro Oncol       Date:  2020-01-11       Impact factor: 12.300

9.  Genetic associations of T cell cancer immune response with tumor aggressiveness in localized prostate cancer patients and disease reclassification in an active surveillance cohort.

Authors:  Qinchuan Wang; Justin R Gregg; Jian Gu; Yuanqing Ye; David W Chang; John W Davis; Timothy C Thompson; Jeri Kim; Christopher J Logothetis; Xifeng Wu
Journal:  Oncoimmunology       Date:  2018-10-29       Impact factor: 8.110

10.  NFATc2 is an intrinsic regulator of melanoma dedifferentiation.

Authors:  V Perotti; P Baldassari; A Molla; C Vegetti; I Bersani; A Maurichi; M Santinami; A Anichini; R Mortarini
Journal:  Oncogene       Date:  2015-09-21       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.